CEP126

Across TCGA pan-cancer cohorts, CEP126 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CEP126 data layer compared with 21 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher CEP126 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CEP126 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

OV, UCEC, and COAD are the cancer types where CEP126 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.118	0.844	<.001	36	view →
UCEC	DFS	Median	All	0.977	0.826	.008	34	view →
COAD	OS	Median	IV	0.056	0.659	<.001	12	view →
DLBC	DFS	Median	All	0.022	0.809	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	OS	Median	All	1.000	0.353	.012	5	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CEP126–OV (OS)

Open the OV breakdown →